Amgen (AMGN) PT Raised to $275 at Oppenheimer on Olpasiran Potential

April 5, 2021 6:44 AM EDT
Get Alerts AMGN Hot Sheet
Price: $312.47 -0.71%

Rating Summary:
    21 Buy, 13 Hold, 4 Sell

Rating Trend: Down Down

Today's Overall Ratings:
    Up: 14 | Down: 13 | New: 8
Join SI Premium – FREE

Oppenheimer analyst Jay Olson raised the price target on Amgen (NASDAQ: AMGN) to $275.00 on the belief that Olpasiran has the potential to drive upside while noting multiple other catalysts.

The analyst stated "We're especially encouraged by olpasiran, which is an siRNA that inhibits Lp(a) for ASCVD patients with an ongoing Ph2 trial. We forecast risk-adjusted (41% POS estimate) olpasiran sales of $1.5B in 2030. Additional potential value-drivers include bemarituzumab from FPRX acquisition, BiTE program, inflammation candidates, and biosimilars. We update our model with the addition of olpasiran (AMG 890) driving our new $275 PT."

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst EPS Change, Analyst PT Change

Related Entities

Definitive Agreement